

TABLE A.3.—UGDP DATA: CARDIOVASCULAR FAILURE RATES BY SEX AND CLINIC FOR EACH TREATMENT

Clinic and treatment group	Both sexes				Males				Females			
	Total number of patients	Total number of failures	Total time at risk, quarter-years	Failure rate (in thousands)	Total number of patients	Total number of failures	Total time at risk, quarter-years	Failure rate (in thousands)	Total number of patients	Total number of failures	Total time at risk, quarter-years	Failure rate (in thousands)
Boston:												
Placebo	15	1	391.0	2.6	10	1	260.3	3.8	5	0	130.7	0
Tolbutamide	17	4	385.7	10.4	6	1	133.9	7.5	11	3	251.8	11.9
Standard dose insulin	16	1	412.9	2.4	4	0	96.4	0	12	1	316.4	3.2
Variable dose insulin	15	1	397.9	2.5	6	0	138.2	0	9	1	239.7	4.2
Minneapolis:												
Placebo	22	2	522.7	3.8	9	2	200.3	10.0	13	0	322.3	0
Tolbutamide	24	6	461.6	13.0	9	2	166.2	12.0	15	4	295.5	13.5
Standard dose insulin	24	2	565.1	3.5	5	1	126.9	7.9	18	1	439.2	2.3
Variable dose insulin	24	2	582.4	3.4	5	0	124.3	0	19	2	458.1	4.4
New York:												
Placebo	22	3	553.7	5.4	4	2	86.4	23.2	18	1	467.3	2.1
Tolbutamide	20	2	516.2	3.9	6	2	130.7	13.3	14	0	365.5	0
Standard dose insulin	21	0	512.6	0	10	0	237.5	0	11	0	275.1	0
Variable dose insulin	22	0	565.2	0	2	0	46.1	0	20	0	519.1	0
Williamson:												
Placebo	23	1	629.1	1.6	9	1	209.4	4.8	14	0	419.8	0
Tolbutamide	22	3	601.8	5.0	8	2	210.9	9.5	14	1	390.9	2.6
Standard dose insulin	23	2	601.6	3.3	6	1	138.5	7.2	17	1	463.1	2.2
Variable dose insulin	24	3	610.4	4.9	4	2	70.3	28.4	20	1	540.1	1.9
Cincinnati:												
Placebo	23	2	550.4	3.6	7	0	166.6	0	16	2	383.8	5.2
Tolbutamide	22	7	572.9	12.2	6	3	163.3	18.4	16	4	409.6	9.8
Standard dose insulin	24	4	646.9	6.2	4	1	88.5	10.2	20	3	548.4	5.5
Variable dose insulin	21	4	581.6	6.9	5	0	166.5	0	16	4	415.1	9.6
Cleveland:												
Placebo	19	0	521.5	0	0	0	0	-----	19	0	521.5	0
Tolbutamide	18	1	461.8	2.2	3	0	77.3	0	15	1	384.5	2.6
Standard dose insulin	20	0	548.2	0	1	0	25.1	0	19	0	523.0	0
Variable dose insulin	20	1	528.7	1.9	5	0	126.9	0	15	1	401.7	2.5